NCT00550199View on ClinicalTrials.gov

LBH589 and Gemcitabine in the Treatment of Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Solid Tumors
Interventions
DRUG

LBH589, Gemcitabine

Phase I dose escalation: LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.

Trial Locations (1)

37023

Tennessee Oncology, PLLC, Nashville

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER